462 related articles for article (PubMed ID: 27158042)
1. Alpha-synuclein-based models of Parkinson's disease.
Dehay B; Fernagut PO
Rev Neurol (Paris); 2016; 172(6-7):371-8. PubMed ID: 27158042
[TBL] [Abstract][Full Text] [Related]
2. α-Synuclein in Parkinson's disease: pathogenic function and translation into animal models.
Eschbach J; Danzer KM
Neurodegener Dis; 2014; 14(1):1-17. PubMed ID: 24080741
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
4. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
[TBL] [Abstract][Full Text] [Related]
5. The yin and yang of α-synuclein-associated epigenetics in Parkinson's disease.
Pavlou MAS; Pinho R; Paiva I; Outeiro TF
Brain; 2017 Apr; 140(4):878-886. PubMed ID: 27585855
[TBL] [Abstract][Full Text] [Related]
6. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
8. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
[TBL] [Abstract][Full Text] [Related]
9. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
10. A Drosophila model of Parkinson's disease.
Feany MB; Bender WW
Nature; 2000 Mar; 404(6776):394-8. PubMed ID: 10746727
[TBL] [Abstract][Full Text] [Related]
11. α-synuclein expression from a single copy transgene increases sensitivity to stress and accelerates neuronal loss in genetic models of Parkinson's disease.
Cooper JF; Spielbauer KK; Senchuk MM; Nadarajan S; Colaiácovo MP; Van Raamsdonk JM
Exp Neurol; 2018 Dec; 310():58-69. PubMed ID: 30194957
[TBL] [Abstract][Full Text] [Related]
12. A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.
Henrich MT; Geibl FF; Lee B; Chiu WH; Koprich JB; Brotchie JM; Timmermann L; Decher N; Matschke LA; Oertel WH
Acta Neuropathol Commun; 2018 May; 6(1):39. PubMed ID: 29747690
[TBL] [Abstract][Full Text] [Related]
13. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication.
Fukusumi H; Togo K; Sumida M; Nakamori M; Obika S; Baba K; Shofuda T; Ito D; Okano H; Mochizuki H; Kanemura Y
FEBS Open Bio; 2021 Feb; 11(2):354-366. PubMed ID: 33301617
[TBL] [Abstract][Full Text] [Related]
14. The effect of mutant GBA1 on accumulation and aggregation of α-synuclein.
Maor G; Rapaport D; Horowitz M
Hum Mol Genet; 2019 Jun; 28(11):1768-1781. PubMed ID: 30615125
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
16. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
Schulz-Schaeffer WJ
Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
[TBL] [Abstract][Full Text] [Related]
17. Somatic copy number gains of α-synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains.
Mokretar K; Pease D; Taanman JW; Soenmez A; Ejaz A; Lashley T; Ling H; Gentleman S; Houlden H; Holton JL; Schapira AHV; Nacheva E; Proukakis C
Brain; 2018 Aug; 141(8):2419-2431. PubMed ID: 29917054
[TBL] [Abstract][Full Text] [Related]
18. Extracellular α-synuclein--a possible initiator of inflammation in Parkinson's disease.
Ren WQ; Tian ZM; Yin F; Sun JZ; Zhang JN
Pharmazie; 2016 Feb; 71(2):51-5. PubMed ID: 27004367
[TBL] [Abstract][Full Text] [Related]
19. Back and to the Future: From Neurotoxin-Induced to Human Parkinson's Disease Models.
Airavaara M; Parkkinen I; Konovalova J; Albert K; Chmielarz P; Domanskyi A
Curr Protoc Neurosci; 2020 Mar; 91(1):e88. PubMed ID: 32049438
[TBL] [Abstract][Full Text] [Related]
20. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]